Clinical Trial Update: Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 safety study examining radiation in combination with CP-675,206 infusion for metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CP-675,206

Snippet

Sponsor: University Health Network, Toronto | Conditions: Metastatic Breast Cancer | Phase 1 | Status: TERMINATED